In recent years, immune checkpoint inhibitors targeting programmed cell death protein 1 (PD-1) have been shown to be effective in mCRC patients with DNA repair defects such as deficient mismatch repair (dMMR) or MSI-H CRC [144]. This evidence concerns the gene PDCD1 and colorectal carcinoma.